HRP20171161T1 - Postupak konjugiranja bakterijskih polisaharida s proteinskim nosačima - Google Patents

Postupak konjugiranja bakterijskih polisaharida s proteinskim nosačima Download PDF

Info

Publication number
HRP20171161T1
HRP20171161T1 HRP20171161TT HRP20171161T HRP20171161T1 HR P20171161 T1 HRP20171161 T1 HR P20171161T1 HR P20171161T T HRP20171161T T HR P20171161TT HR P20171161 T HRP20171161 T HR P20171161T HR P20171161 T1 HRP20171161 T1 HR P20171161T1
Authority
HR
Croatia
Prior art keywords
bacterial saccharide
buffer
saccharide
kda
conjugate
Prior art date
Application number
HRP20171161TT
Other languages
English (en)
Inventor
Ralph Leon Biemans
Pierre Duvivier
Ollivier Francis Nicolas Gavard
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42136725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20171161(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of HRP20171161T1 publication Critical patent/HRP20171161T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier

Claims (14)

1. Postupak konjugiranja bakterijskog saharida, naznačen time što obuvaća korake a) reakcija bakterijskog saharida s 0,001-0,7 molarnih ekvivalenata perjodata kako bi se dobio aktivirani bakterijski saharid; b) miješanje aktiviranog bakterijskog saharida s proteinskim nosačem; c) reakcija aktiviranog bakterijskog saharida i proteinskog nosača s reducensom kako bi se dobio konjugat; ili a) reakcija bakterijskog saharida s 0,001-0,7 molarnih ekvivalenata perjodata kako bi se dobio aktivirani bakterijski saharid; b) miješanje aktiviranog bakterijskog saharida sa spojnicom; 2. c’) reakcija aktiviranog bakterijskog saharida sa spojnicom uz upotrebu reducensa kako bi se dobio kompleks bakterijski saharid-spojnica; d) reakcija kompleksa bakterijski saharid-spojnica s proteinskim nosačem kako bi se dobio konjugat; 3. gdje se korak a) provodi u puferu koji ne sadrži aminsku skupinu, gdje je koncentracija pufera između 1 i 100 mM, te gdje je bakterijski saharid saharid 23F iz kapsule bakterije S. pneumoniae.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se pufer bira iz skupine koju čine fosfatni pufer, boratni pufer, acetatni pufer, karbonatni pufer i citratni pufer, gdje pufer može imati koncentraciju između 1 i 50 mM, 1 i 25 mM, 1 i 10 mM, 5 i 15 mM, 8 i 12 mM ili 10-50 mM, ili oko 10 mM.
3. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što je pH u koraku a) pH 3,5-8,0 5,0-7,0 ili pH 5,5-6,5, ili oko pH 6,0.
4. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je prosječna molekulska težina bakterijskog saharida između 1 i 1100 kDa, 100 i 470 kDa, 200 i 300 kDa, 600 i 1100 kDa ili 800 i 1000 kDa nakon koraka a).
5. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je prosječna molekulska težina saharida 23F između 100 i 470 kDa ili 200-300 kDa nakon koraka a).
6. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što se proteinski nosač bira iz skupine koju čine tetanusni toksoid, fragment C tetanusnog toksoida, difterijski toksoid, CRM197, pneumolizin, protein D, PhtD, PhtDE i N19.
7. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što reducens uključuje natrijev cijanoborohidrid ili natrijev triacetoksiborohidrid.
8. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što uključuje dodatni korak e) pročišćavanja konjugata.
9. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što uključuje dodatni korak miješanja konjugata s dodatnim antigensom, gdje dodatni antigeni može uključivati u najmanju ruku 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 ili 20 S. pneumoniae saharide, koji se biraju iz skupine koju čine 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F i 33F.
10. Postupak u skladu s patentnim zahtjevom 9, naznačen time što dodatni antigeni uključuju jedan ili više proteina iz bakterije S. pneumoniae, koji se biraju iz skupine koju čine obitelj polihistidinske trijade (PhtX), obitelj kolinski vežućeg proteina (CbpX), skraćeni CbpX, obitelj LytX, skraćeni LytX, kimerini proteini (ili fuzije) skraćeni CbpX-skraćeni LytX, pneumolizin (Ply), PspA, PsaA, Sp128, Sp101, Sp130, Sp125 i Sp133.
11. Postupak u skladu s patentnim zahtjevom 9 ili patentnim zahtjevom 10, naznačen time što dodatni antigeni uključuju saharide 1, 4, 5, 6B, 7F, 9V, 14, 18C i 19F iz bakterije S. pneumoniae.
12. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-11, naznačen time što se sastoji u koraku reakcije bakterijskog saharida s 0,1-0,5 molarnih ekvivalenata perjodata kako bi se dobio aktivirani bakterijski saharid.
13. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što smanjuje učinak smanjivanja na bakterijski saharid.
14. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što se konjugat pomiješa s adjuvansom ili farmaceutski prihvatljivom pomoćnom tvari.
HRP20171161TT 2010-03-09 2017-07-28 Postupak konjugiranja bakterijskih polisaharida s proteinskim nosačima HRP20171161T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1003922.0A GB201003922D0 (en) 2010-03-09 2010-03-09 Conjugation process
EP14181075.4A EP2815762B1 (en) 2010-03-09 2011-03-07 Conjugation process of bacterial polysaccharides to carrier proteins

Publications (1)

Publication Number Publication Date
HRP20171161T1 true HRP20171161T1 (hr) 2017-10-06

Family

ID=42136725

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150935TT HRP20150935T1 (en) 2010-03-09 2015-09-07 Conjugation process of bacterial polysaccharides to carrier proteins
HRP20171161TT HRP20171161T1 (hr) 2010-03-09 2017-07-28 Postupak konjugiranja bakterijskih polisaharida s proteinskim nosačima

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20150935TT HRP20150935T1 (en) 2010-03-09 2015-09-07 Conjugation process of bacterial polysaccharides to carrier proteins

Country Status (26)

Country Link
US (3) US8753645B2 (hr)
EP (2) EP2544708B1 (hr)
JP (1) JP5698770B2 (hr)
KR (2) KR20130038233A (hr)
CN (1) CN102883745A (hr)
AU (1) AU2011226160B2 (hr)
BR (1) BR112012022358B1 (hr)
CA (1) CA2791926C (hr)
CY (2) CY1116685T1 (hr)
DK (2) DK2544708T3 (hr)
EA (1) EA023059B1 (hr)
ES (2) ES2545221T3 (hr)
GB (1) GB201003922D0 (hr)
HR (2) HRP20150935T1 (hr)
HU (2) HUE027621T2 (hr)
LT (1) LT2815762T (hr)
ME (1) ME02204B (hr)
MX (2) MX2012010388A (hr)
PL (2) PL2815762T3 (hr)
PT (2) PT2815762T (hr)
RS (1) RS54188B1 (hr)
SG (2) SG183476A1 (hr)
SI (2) SI2815762T1 (hr)
SM (1) SMT201500211B (hr)
WO (1) WO2011110531A2 (hr)
ZA (1) ZA201206637B (hr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
BRPI0612669B8 (pt) 2005-06-27 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, composição, e composição liofilizada
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
PT3246044T (pt) 2010-08-23 2021-02-15 Wyeth Llc Formulações estáveis de antigénios de rlp2086 de neisseria meningitidis
MX362802B (es) 2010-09-10 2019-02-13 Wyeth Llc Star Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis.
GB201103836D0 (en) * 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN104736180A (zh) * 2012-05-22 2015-06-24 诺华股份有限公司 脑膜炎球菌血清组x偶联物
WO2014097099A2 (en) * 2012-12-20 2014-06-26 Pfizer Inc. Glycoconjugation process
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
PL404247A1 (pl) 2013-06-07 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
PL3096783T3 (pl) 2014-01-21 2021-12-13 Pfizer Inc. Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
SG11201604728XA (en) 2014-01-21 2016-08-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102049825B1 (ko) * 2014-01-21 2019-12-03 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
JP7164200B2 (ja) 2016-03-31 2022-11-01 ポゴナ， エルエルシー サッカライド－ポリペプチドコンジュゲートの組成物およびその使用の方法
SG11201901394XA (en) 2016-09-02 2019-03-28 Sanofi Pasteur Inc Neisseria meningitidis vaccine
WO2018126229A2 (en) 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
WO2018144438A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
PE20201338A1 (es) 2017-12-06 2020-11-25 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos
WO2020010016A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Self-adjuvanted immunogenic conjugates
WO2020010000A1 (en) 2018-07-04 2020-01-09 Sutrovax, Inc. Improved methods for the preparation of immunogenic conjugates
BR112020026899A2 (pt) 2018-07-04 2021-03-30 Vaxcyte, Inc. Melhorias em conjugados imunogênicos
CN113453708A (zh) 2018-12-19 2021-09-28 默沙东公司 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
NZ249704A (en) 1992-02-11 1996-11-26 Jackson H M Found Military Med A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DK0658118T3 (da) 1992-08-31 2002-05-06 Baxter Healthcare Sa Vaccine mod Neisseria meningitidis, gruppe C
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
DE69431624T2 (de) 1993-05-18 2003-07-10 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung
ES2210262T3 (es) 1993-09-22 2004-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas.
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
WO1996029094A1 (en) 1995-03-22 1996-09-26 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JP4012252B2 (ja) 1996-06-18 2007-11-21 アルザ コーポレイション 薬剤の経皮放出又はサンプリングを高めるための装置
WO1998018930A2 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CA2271167C (en) 1996-12-20 2007-01-09 Alza Corporation Device and method for enhancing transdermal agent flux
DK0959905T3 (da) 1997-01-21 2010-04-06 Sanofi Pasteur Polysaccharid-peptid-konjugater
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
WO1998055606A2 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2312900A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
KR100704826B1 (ko) 1998-08-19 2007-04-09 박스터 헬쓰케어 에스.에이. Ｎ-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트
JP4689044B2 (ja) 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
EP1163000B1 (en) 1999-03-19 2008-02-27 GlaxoSmithKline Biologicals S.A. Vaccine against antigens from bacteriae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
KR20050086427A (ko) 2002-11-07 2005-08-30 시너지 아메리카 인코포레이티드 폐렴균의 감염 치료 또는 예방용 조성물 및 방법
CN1798563A (zh) 2003-05-15 2006-07-05 独立行政法人科学技术振兴机构 免疫刺激剂
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
BRPI0413309B8 (pt) 2003-08-06 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services método para a preparação de uma vacina conjugada de polissacarídeo-proteína
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI445545B (zh) 2005-04-08 2014-07-21 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
BRPI0612669B8 (pt) * 2005-06-27 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, composição, e composição liofilizada
US20090010959A1 (en) 2005-12-22 2009-01-08 Ralph Leon Biemans Pneumococcal Polysaccharide Conjugate Vaccine
CN105267974A (zh) 2007-06-20 2016-01-27 辉瑞爱尔兰制药公司 用于缀合疫苗的经过修饰的多糖
BRPI0813307C1 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
GB201003922D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process

Also Published As

Publication number Publication date
EA201290692A1 (ru) 2013-06-28
AU2011226160B2 (en) 2013-05-23
WO2011110531A2 (en) 2011-09-15
KR20130038233A (ko) 2013-04-17
ZA201206637B (en) 2016-09-28
SMT201500211B (it) 2015-10-30
EP2815762A2 (en) 2014-12-24
SG10201500413UA (en) 2015-03-30
RS54188B1 (en) 2015-12-31
MX351345B (es) 2017-10-11
US20140186390A1 (en) 2014-07-03
AU2011226160A1 (en) 2012-10-25
EP2815762A3 (en) 2015-03-25
CY1119244T1 (el) 2018-02-14
ME02204B (me) 2016-02-20
US20120321660A1 (en) 2012-12-20
JP2013521394A (ja) 2013-06-10
PL2815762T3 (pl) 2017-10-31
US8753645B2 (en) 2014-06-17
EP2815762B1 (en) 2017-05-31
US9265839B2 (en) 2016-02-23
BR112012022358B1 (pt) 2021-12-14
HUE035971T2 (en) 2018-05-28
DK2544708T3 (en) 2015-08-24
SI2544708T1 (sl) 2015-10-30
EP2544708B1 (en) 2015-06-24
EP2544708A2 (en) 2013-01-16
ES2545221T3 (es) 2015-09-09
JP5698770B2 (ja) 2015-04-08
SI2815762T1 (sl) 2017-09-29
US20140186389A1 (en) 2014-07-03
ES2636940T3 (es) 2017-10-10
CA2791926A1 (en) 2011-09-15
CA2791926C (en) 2015-09-29
PT2544708E (pt) 2015-10-09
US9265840B2 (en) 2016-02-23
SG183476A1 (en) 2012-09-27
DK2815762T3 (en) 2017-09-11
PL2544708T3 (pl) 2015-11-30
LT2815762T (lt) 2017-08-25
CN102883745A (zh) 2013-01-16
CY1116685T1 (el) 2017-03-15
GB201003922D0 (en) 2010-04-21
EA023059B1 (ru) 2016-04-29
MX2012010388A (es) 2012-10-10
HUE027621T2 (en) 2016-11-28
BR112012022358A2 (pt) 2020-07-28
WO2011110531A3 (en) 2012-03-08
PT2815762T (pt) 2017-08-28
HRP20150935T1 (en) 2015-09-25
KR20160005793A (ko) 2016-01-15

Similar Documents

Publication Publication Date Title
HRP20171161T1 (hr) Postupak konjugiranja bakterijskih polisaharida s proteinskim nosačima
JP2009520761A5 (hr)
JP2009520760A5 (hr)
HRP20150587T1 (hr) Postupak konjugiranja bakterijskog antigena s proteinskim nosaäśem
JP2010513550A5 (hr)
CY1118535T1 (el) Εμβολιο streptococcus pneumoniae
MX2020002558A (es) Procesos para la formulacion de polisacaridos neumococicos para la conjugacion a una proteina transportadora.
JP2018531315A5 (hr)
KR102634811B1 (ko) 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
EP2417983B1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
JP2023036953A5 (hr)
JP2015536312A5 (hr)
AR116043A2 (es) Composición de vacuna conjugada de polisacárido-proteína neumocócica 15-valente
SA517390539B1 (ar) لقاح مقترن متعدد التكافؤ لبكتيريا المكورات الرئوية
MX2009006547A (es) Composicion conjugada polisacarido-proteina neumococica multivalente.
MX2009013949A (es) Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
MX336934B (es) Composicion conjugada polisacarido-proteina neumococica multivalente.
CN103083652B (zh) 一种以异型双功能试剂为连接桥的脑膜炎多糖结合疫苗及其制备方法
PE20211888A1 (es) Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y sus metodos de uso
MY194920A (en) Polysaccharide ? protein conjugates with enhanced immunogenicity and rapid high yielding process thereof
US20150344530A1 (en) Synthetic Peptides as Carriers for Conjugation with Polysaccharides
Lees et al. Conjugation chemistry
IN2013DE03047A (hr)
Guo Sino-Pakistan Relationship Was Not a Five-Year Plan